Adherence to dual antiplatelet therapy: can we do better?

References

• Campo G, Saia F, Guastaroba P et al. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch. Intern. Med. 171(21), 1948–1949 (2011).
   PubMedGoogle Scholar
• Campo G, Valgimigli M, Frangione A et al. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). J. Am. Coll. Cardiol. 55(3), 255–256 (2010).
   PubMed Web of Science ®Google Scholar
• Campo G, Fileti L, Valgimigli M et al. Poor response to clopidogrel: current and future options for its management. J. Thromb. Thrombolysis. 30(3), 319–331 (2010).
   PubMed Web of Science ®Google Scholar
• Campo G, Miccoli M, Tebaldi M et al. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22(6), 399–407 (2011).
   PubMed Web of Science ®Google Scholar
• Newby LK, Lapointe NMA, Chen AY et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113(2), 203–212 (2006).
   PubMed Web of Science ®Google Scholar
• Spertus JA, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113(24), 2803–2809 (2006).
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N. Engl. J. Med. 339(23), 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for Percutaneous Coronary Intervention. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58(24), e44–e122 (2011).
   PubMed Web of Science ®Google Scholar
• Mehta S, Yusuf S, Peters R et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• O'gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-Elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 61(4), e78–e140 (2013).
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23), 2999–3054 (2011).
   PubMed Web of Science ®Google Scholar
• Ko DT, Chiu M, Guo H, Austin PC, Marquis J-F, Tu JV. Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents. Am. Heart J. 158(4), 592–598, e591 (2009).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584–2591 (2006).
   PubMed Web of Science ®Google Scholar
• Ong AT, Van Domburg RT, Aoki J, Sonnenschein K, Lemos PA, Serruys PW. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J. Am. Coll. Cardiol. 47(7), 1356–1360 (2006).
   PubMed Web of Science ®Google Scholar
• Campo G, Napoli N, Serenelli C, Tebaldi M, Ferrari R. Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. Int. J. Cardiol. 167(1), 296–297 (2013).
   PubMed Web of Science ®Google Scholar
• Nilsen DW, Melberg T, Larsen AI, Barvik S, Bonarjee V. Late complications following the deployment of drug eluting stents. Int. J. Cardiol. 109(3), 398–401 (2006).
   PubMed Web of Science ®Google Scholar
• Ong AT, Aoki J, Mcfadden EP, Serruys PW. Classification and current treatment options of in-stent restenosis. Present status and future perspectives. Herz 29(2), 187–194 (2004).
   PubMed Web of Science ®Google Scholar
• Dores H, Raposo L, Campante Teles R et al. Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry. J. Invasive Cardiol. 25(7), 330–336 (2013).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 127, e6–6245 (2013).
   PubMed Web of Science ®Google Scholar
• Etemad LR, Mccollam PL. Predictors of high-cost managed care patients with acute coronary syndrome. Curr. Med. Res. Opin. 21(12), 1977–1984 (2005).
   PubMed Web of Science ®Google Scholar
• Quadros AS, Welter DI, Camozzatto FO et al. Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. The Am. J. Cardiol. 107(5), 685–689 (2011).
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117(8), 1028–1036 (2008).
   PubMed Web of Science ®Google Scholar
• Shroff A, Ali A, Groo VL. Clopidogrel adherence following percutaneous coronary intervention with a drug-eluting stent in a VA Medical Center. J. Pharma. Technol. 25, 164–168 (2009).
   Google Scholar
• Muntner P, Mann DM, Woodward M et al. Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am. J. Cardiol. 108(6), 822–827 (2011).
   PubMed Web of Science ®Google Scholar
• Campo G, Guastaroba P, Marzocchi A et al. Impact of chronic obstructive pulmonary disease on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary Intervention. Chest doi:10.1378/chest.12-2313 (2013) ( Epub ahead of print).
   Google Scholar
• Fox KaA, Mehta SR, Peters R et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 110(10), 1202–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Ben-Dor I, Torguson R, Scheinowitz M et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am. Heart J. 159(5), 871–875 (2010).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Mccabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Rossini R, Capodanno D, Lettieri C et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am. J. Cardiol. 107(2), 186–194 (2011).
   PubMed Web of Science ®Google Scholar
• Vicenzi MN, Ribitsch D, Luha O, Klein W, Metzler H. Coronary artery stenting before noncardiac surgery: more threat than safety? Anesthesiology 94(2), 367–368 (2001).
   PubMed Web of Science ®Google Scholar
• Van Kuijk JP, Flu WJ, Schouten O et al. Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents. Am. J. Cardiol. 104(9), 1229–1234 (2009).
   PubMed Web of Science ®Google Scholar
• Cruden NLM, Harding SA, Flapan AD et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ. Cardiovasc. Interv. 3(3), 236–242 (2010).
   PubMed Web of Science ®Google Scholar
• Aghabekyan S, Thompson ME, Abrahamyan L. Medication noncompliance and patient satisfaction following percutaneous coronary intervention. J. Interv. Cardiol. 25(5), 469–475 (2012).
   PubMed Web of Science ®Google Scholar
• Grines CL, Bonow RO, Casey DE et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115(6), 813–818 (2007).
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 119(23), 3028–3035 (2009).
   PubMed Web of Science ®Google Scholar
• Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 291(11), 1358–1367 (2004).
   PubMed Web of Science ®Google Scholar
• Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 111(2), 179–185 (2005).
   PubMed Web of Science ®Google Scholar
• Chernew ME, Juster IA, Shah M et al. Evidence that value-based insurance can be effective. Health Aff. 29(3), 530–536 (2010).
   Web of Science ®Google Scholar
• Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am. J. Manag. care 16(4), 290–297 (2010).
   PubMed Web of Science ®Google Scholar
• Amin AP, Spertus JA, Cohen DJ et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch. Intern. Med. 172(15), 1145–1152 (2012).
   PubMedGoogle Scholar
• Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J. Am. Coll. Cardiol. 60(15), 1340–1348 (2012).
   PubMed Web of Science ®Google Scholar
• Kedhi E, Joesoef KS, Mcfadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 375(9710), 201–209 (2010).
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Percoco G et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am. Heart J. 160(5), 804–811 (2010).
   PubMed Web of Science ®Google Scholar
• Ferreira-Gonzalez I, Marsal JR, Ribera A et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 122, 1017–1025 (2010).
   PubMed Web of Science ®Google Scholar